Elsevier

European Urology

Volume 67, Issue 1, January 2015, Pages 17-20
European Urology

Platinum Priority – Brief Correspondence
Editorial by Alexander Laird, David. J. Harrison and Grant D. Stewart on pp. 21–22 of this issue
A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition

https://doi.org/10.1016/j.eururo.2014.06.041Get rights and content

Abstract

Patients with clear cell renal cell carcinoma (ccRCC) have divergent survival outcomes and therapeutic responses, which may be determined by underlying molecular diversity. We aimed to develop a practical molecular assay that can identify subtypes with differential prognosis and response to targeted therapy. Whole-genome expression analysis of formalin-fixed paraffin-embedded (FFPE) material from 55 ccRCC patients was performed and two molecular subtypes with differential clinical outcomes were identified by hierarchical clustering. An eight-gene quantitative polymerase chain reaction assay for classification into two subtypes was developed for FFPE material. The primary objective was to assess assay performance by correlating ccRCC prognostic subtypes to cancer-specific survival (CSS) and, for patients receiving targeted therapy, radiologic response. In three validation cohorts, patients could be distinguished into prognostic subtypes with differential CSS (Singapore General Hospital FFPE cohort: n = 224; p = 1.48 × 10−8; the Cancer Genome Atlas RNA-Sequencing cohort: n = 419; p = 3.06 × 10−7; Van Andel Research Institute microarray cohort: n = 174; p = 0.00743). For 48 patients receiving tyrosine kinase inhibitor (TKI) treatment, the prognostic classification was associated with radiologic response to treatment (p = 5.96 × 10−4) and prolonged survival on TKI treatment (p = 0.019). The multigene assay can classify ccRCCs into clinical prognostic subtypes, which may be predictive of response in patients receiving TKI therapy.

Cited by (24)

  • Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting

    2018, Clinical Genitourinary Cancer
    Citation Excerpt :

    Although these ccRCC driver mutations are typically subclonal, a parallel convergent evolution of subclones is often present.13 On a transcriptomic level, other groups have demonstrated the existence of prognostic molecular subtypes of ccRCC in the postnephrectomy setting, based on cluster analysis of whole genome mRNA expression data.14-17 Brooks et al18 have proposed a 34-gene classifier, Clearcode34, which classifies tumors into a good-risk (ccA) or poor-risk (ccB) group.

  • Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study

    2017, Clinical Genitourinary Cancer
    Citation Excerpt :

    It is known that RCC is originated by multiple clones progressing simultaneously that develop different characteristics to promote growth and metastases. Although efforts are currently under way to create prognostic panels that analyze multiple genes to identify genetic signatures associated with RCC prognosis and therapeutic possibilities,32,33 these panels are still no better than currently established clinical prognostic factors and must be validated in prospective studies before they can be applied in clinical practice. In our study, stages III to IV as well as Fuhrman nuclear grades 3 and 4 were closely associated with shorter OS, DSS, and PFS and were shown in the Cox analysis to be the only independent variables associated with a higher risk of death or progression.

  • Postoperative Surveillance for Renal Cell Carcinoma

    2017, Urologic Clinics of North America
    Citation Excerpt :

    Indeed, a 16-gene assay36 and 34-gene assay37 developed for clear cell RCC show improvement in prognostication over clinical indicators. Among a subset of patients, a multigene panel generated to distinguish prognostic subtypes of clear cell RCC was found to be associated with radiographic response to tyrosine kinase inhibitor therapy and survival.38 Although these personalized tools show promise in reducing costs and radiation exposure by focusing surveillance to those at greatest risk, disadvantages of access and cost from implementing widespread genetic testing will be difficult to offset.

  • Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma

    2015, Human Pathology
    Citation Excerpt :

    Recent evidence has shown the presence of molecular subtypes of ccRCC of distinct prognosis and differential response to targeted therapy. Although these subtypes are indistinguishable by morphology, the use of molecular markers can help to stratify these subtypes with significant clinical implications [24-28]. Our results are in line with recent literature showing that Pfn1 affects cell migration and invasion and tumor aggressive behavior [29].

  • Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective

    2015, Surgical Pathology Clinics
    Citation Excerpt :

    An external validation set confirmed this association and this germline alteration may be incorporated in future prognostic tools or used to plan further adjuvant clinical trials.23 More elaborate approaches to assess recurrence risk, such as gene expression signatures, have been reported, with 3 models already available,24–26 including a 16-gene signature, recently externally validated in stage I–III ccRCC.27 These tools, however, are not currently available in clinical practice, and, given the lack of approved adjuvant therapy, the relevance of these signatures is limited to the ability of providing additional prognostic information without direct influence on therapeutic or monitoring guidelines.

View all citing articles on Scopus
View full text